Market Size Estimation:
In this report, the global potential size for the human microbiome market was calculated using the epidemiology approach.
# Key indications were identified for which microbiome therapy clinical trials are underway
# For respective disease categories, estimating the potential market for microbiome-based drugs from existing non-microbiome-based drugs market Microbiome therapeutics are likely to be adopted by a set of patients who show side-effects for existing therapies. Therefore, the percentage of the patient population showing some side-effects with existing therapies was identified. This percentage was then applied to the total therapy market to derive the human microbiome's total addressable market.
# To calculate the total market for microbiome therapy, the penetration rate for microbiome therapies was applied to the total addressable market
# Primary experts then validated this approach.
Individual shares of each product, disease, region, and application were arrived at based on parameters such as product pipeline, clinical trials progress, target indications, funding scenario, and research intensity in the microbiome.
Projected Surge in Revenue Generation:
The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029.
Download PDF [email protected]
Major Growth Driving Factors:
Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.
After arriving at the overall market size-using the market size estimation processes explained above-the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides of the human microbiome market.
Research Methodologies Followed for This Study:
In the primary research process, various sources from the supply sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, technology & innovation directors, personnel from research organizations, physicians, academic institutes, and related key executives from various key companies and organizations operating in the human microbiome market.
The secondary sources referred to for this research study include publications from government sources such as the World Health Organization (WHO), Human Microbiome Project (HMP), Organization for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA), ClinicalTrials.gov, Expert Interviews, and MarketsandMarkets Analysis; business magazines and research journals; press releases; and trade, business, and professional associations.
Secondary data was collected and analyzed to arrive at the global human microbiome market's overall size, which was validated through primary research.
# In 2022, OptiBiotix Health Plc. signed an exclusive sales and distribution agreement with Nahdi Medical Co. To help tackle the obesity epidemic, the company’s GoFigure and SlimBiome Medical weight management products will be available in the KSA from early 2022 through the new agreement with Nahdi.
# In 2020, 4D pharma merged with Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will support and accelerate the ongoing development of 4D pharma’s Live Biotherapeutic. Live Biotherapeutics is a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment, or cure of a disease.
# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.
Request Sample [email protected]
The Asia Pacific region is the fastest-growing region of human microbiome research spending market from 2023 to 2029.
Based on region, the global human microbiome research spending market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the global human microbiome research spending market in 2021. In 2021, the Asia Pacific region is estimated to grow at the highest CAGR in the human microbiome research spending from 2023-2029. Factors such as increasing focus on microbiome research and initiatives taken by public and private organizations to increase awareness regarding microbiome therapeutics, are driving the growth of the human microbiome market in the Asia Pacific (APAC) region.
The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).